Differential diagnosis of hypercalcemia in a patient with CKD G5D
https://doi.org/10.14341/omet12742
Abstract
Patients with chronic kidney disease are characterized by the development of mineral disorders due to a decrease in the number of functioning nephrons. These changes manifest by the development of secondary hyperparathyroidism (the overproduction of intact parathyroid hormone (PTH) associated with the serum hypocalcemia, hyperphosphatemia), dysfunctional vitamin D metabolism, bone mineralization and also extraosseous calcifications. Decreased serum PTH levels associated with hypercalcemia are suspicious for adynamic bone disease, but at the same time requires an extended differential diagnostic search (e.g. metastatic processes). One of the rare causes of hypercalcemia is a defect in 24-hydroxylase (CYP24A1). We present a case of a patient on hemodialysis with atypical secondary hyperparathyroidism and an established CYP24A1 defect.
About the Authors
A. K. Eremkina
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Annа K. Eremkina - MD, PhD; eLibrary SPIN: 8848-2660.
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
A. M. Gorbacheva
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Annа M. Gorbacheva - MD; eLibrary SPIN: 4568-4179.
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
D. V. Lisina
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Daria V. Lisina - resident.
11 Dm. Ulyanova street, 117036 Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
A. A. Povaliaeva
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Alexandra A. Povaliaeva - MD; eLibrary SPIN: 1970-2811
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
E. A. Pigarova
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Ekaterina A. Pigarova - MD, PhD; eLibrary SPIN: 6912-6331; Scopus Author ID 55655098500; Researcher ID: T-9424-2018.
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
N. G. Mokrysheva
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Natalia G. Mokrysheva - MD, PhD, Professor; eLibrary SPIN: 5624-3875.
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
References
1. Elias RM, Dalboni MA, Coelho ACE, et al. CKD-MBD: from the Pathogenesis to the Identification and Development of Potential Novel Therapeutic Targets. Current Osteoporosis Reports. 2018;16(6):693-702. doi: https://doi.org/10.1007/s11914-018-0486-0
2. Hruska KA, Sugatani T, Agapova O, Fang Y. The chronic kidney disease — Mineral bone disorder (CKD-MBD): Advances in pathophysiology. Bone. 2017;100:80-86. doi: https://doi.org/10.1016/j.bone.2017.01.023
3. Moe SM, Wetherill L, Decker BS, et al. Calcium-sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis. Clinical Journal of the American Society of Nephrology. 2017;12(7):1128-1138. doi: https://doi.org/10.2215/CJN.11141016
4. Strugnell SA, Sprague SM, Ashfaq A, et al. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease. American Journal of Nephrology. 2019;49(4):284-293. doi: https://doi.org/10.1159/000499187
5. Jean G, Souberbielle JC, Chazot C. Vitamin D in Chronic Kidney Disease and Dialysis Patients. Nutrients. 2017;9(4):328. doi: https://doi.org/10.3390/nu9040328
6. Navarro JA, Sánchez MJ, Petkov V. Chronic hypercalcaemia in haemodialysis patients. Nefrol Publ Of la Soc Esp Nefrol. 2011;31:752-754. doi: https://doi.org/10.3265/Nefrologia.pre2011.Jun.10974
7. Botushanova AD, Botushanov NP, Yaneva MP. Nuclear Medicine Methods for Evaluation of Abnormal Parathyroid Glands in Patients with Primary and Secondary Hyperparathyroidism. Folia Med (Plovdiv). 2017;59(4):396-404. doi: https://doi.org/10.1515/folmed-2017-0054
8. Mokrysheva NG, Krupinova YuA, Voronkova IA. Parathyroid glands: the normal development, anatomy and histological structure. Endocrine Surgery. 2018;12(4):178-187. (In Russ.). doi: https://doi.org/10.14341/serg10039
9. Rozhinskaya LY, Egshatyan LV. Patologiya kostnoy sistemy pri vtorichnomgiperparatireoze u patsientov s terminal’noystadiey khronicheskoy bolezni pochek na zamestitel’noypochechnoy terapii (gemodializ) (obzor literatury). Osteoporosis and Bone Diseases. 2010;13(2):18-22. (In Russ.). doi: https://doi.org/10.14341/osteo2010218-22
10. Spasovski GB. Bone biopsy as a diagnostic tool in the assessment of renal osteodystrophy. The International Journal of Artificial Organs. 2004;27(11):918-923. doi: https://doi.org/10.1177/039139880402701103
11. Nebeker HG, Coburn JW. Aluminum and renal osteodystrophy. Annual Review of Medicine. 1986;37:79-95. doi: https://doi.org/10.1146/annurev.me.37.020186.000455
12. Brandenburg VM, Floege J. Adynamic bone disease-bone and beyond. NDT Plus. 2008;1(3):135-147. doi: https://doi.org/10.1093/ndtplus/sfn040
13. Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International. 2006;69(11):1945-53. doi: https://doi.org/10.1038/sj.ki.5000414
14. Spasovski GB, Bervoets AR, Behets GJ, et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrology Dialysis Transplantation. 2003;18(6):1159-1166. doi: https://doi.org/10.1093/ndt/gfg116
15. Torres A, Lorenzo V, Hernández D, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney International. 1995;47(5):1434-1442. doi: https://doi.org/10.1038/ki.1995.201
16. Goodman WG. Comments on plasma parathyroid hormone levels and their relationship to bone histopathology among patients undergoing dialysis. Seminars in Dialysis. 2007;20(1):1-4. doi: https://doi.org/10.1111/j.1525-139X.2007.00230.x
17. Schwarz C, Sulzbacher I, Oberbauer R. Diagnosis of renal osteodystrophy. European Journal of Clinical Investigation. 2006;36(2):13-22. doi: https://doi.org/10.1111/j.1365-2362.2006.01666.x
18. Vetter T, Lohse MJ. Magnesium and the parathyroid. Current Opinion in Nephrology and Hypertension. 2002;11(4):403-410. doi: https://doi.org/10.1097/00041552-200207000-00006
19. Dinour D, Beckerman P, Ganon L, et al. Loss-of-function mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis. The Journal of Urology. 2013;190(2):552-557. doi: https://doi.org/10.1016/j.juro.2013.02.3188
20. Tebben PJ, Singh RJ, Kumar R. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment. Endocrine Reviews. 2016;37(5):521-547. doi: https://doi.org/10.1210/er.2016-1070
Supplementary files
Review
For citations:
Eremkina A.K., Gorbacheva A.M., Lisina D.V., Povaliaeva A.A., Pigarova E.A., Mokrysheva N.G. Differential diagnosis of hypercalcemia in a patient with CKD G5D. Obesity and metabolism. 2021;18(4):425-431. (In Russ.) https://doi.org/10.14341/omet12742
Views:
2711
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
